Pfizer could use existing U.S. production to counter tariff hit, Reuters reports

Pfizer (PFE) may move overseas manufacturing to its existing plants in the U.S., if required, as the Trump administration threatens numerous tariffs on imported goods, Reuters’ Christy Santhosh reports. CEO Albert Bourla said Monday that “We have the capabilities here and the manufacturing sites are operating in good capacity right now. If something happens, we will try to mitigate it by transferring from manufacturing sites outside to the manufacturing sites here.” Pfizer has 10 manufacturing sites and two distribution centers in the U.S., the report notes.